Evidence map›Paper›PMID 31548397›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Inhibition of Δ24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution.

Andreas Körner, Enchen Zhou, Christoph Müller, Yassene Mohammed, Sandra Herceg, Franz Bracher, Patrick C N Rensen, Yanan Wang, Valbona Mirakaj, Martin Giera

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andreas KörnerDepartment of Anesthesiology and Intensive Care Medicine, Molecular Intensive Care Medicine, Eberhard Karls University Tübingen, 72072 Tübingen, Germany.
Enchen ZhouDepartment of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
Christoph MüllerDepartment of Pharmacy-Center for Drug Research, Ludwig Maximilians University Munich, 81377 Munich, Germany.
Yassene MohammedCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
Sandra HercegDepartment of Pharmacy-Center for Drug Research, Ludwig Maximilians University Munich, 81377 Munich, Germany.
Franz BracherDepartment of Pharmacy-Center for Drug Research, Ludwig Maximilians University Munich, 81377 Munich, Germany.ORCID 0000-0003-0009-8629
Patrick C N RensenDepartment of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
Yanan WangDepartment of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
Valbona MirakajDepartment of Anesthesiology and Intensive Care Medicine, Molecular Intensive Care Medicine, Eberhard Karls University Tübingen, 72072 Tübingen, Germany.
Martin GieraCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZA Leiden, The Netherlands m.a.giera@lumc.nl.ORCID 0000-0003-1684-1894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting metabolism through bioactive key metabolites is an upcoming future therapeutic strategy. We questioned how modifying intracellular lipid metabolism could be a possible means for alleviating inflammation. Using a recently developed chemical probe (SH42), we inhibited distal cholesterol biosynthesis through selective inhibition of Δ

Indexed as

Gene Expression RegulationAnimalsAnti-Inflammatory AgentsArachidonate 12-LipoxygenaseArachidonate 15-LipoxygenaseCholesterolDisease Models, AnimalFemaleGene Expression ProfilingHumansInflammation MediatorsLipid MetabolismLipidsLipogenesisLiver X ReceptorsMiceALOX12 protein, humanALOX15 protein, humanAnti-Inflammatory AgentsArachidonate 12-LipoxygenaseArachidonate 15-LipoxygenaseCholesterolDHCR24 protein, humanInflammation MediatorsLipidsLiver X ReceptorsNerve Tissue ProteinsOxidoreductases Acting on CH-CH Group Donorscholesteroldesmosterolinflammation resolutionlipid mediatorPUFA

Identifiers

PMID31548397
PMCPMC6789642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.